Herein, we performed this clinical investigation to assess the long-term effectiveness and safety of SGLT-2 inhibitors (SGLT-2i) in a Romanian population of subjects affected by T2DM. This evidence concerns the gene SLC5A2 and type 2 diabetes mellitus.